TGA reviews metformin kidney warnings

The TGA is to review warnings for metformin about its use in patients with mild to moderate renal impairment and risk of lactic acidosis following changes made by the FDA.

In a statement, the US regulator said it was dropping some warnings and revising statements on the labels referring to the criteria by which renal impairment was measured.

The move follows concerns that overcautious warnings were deterring